Navigation Links
NeurogesX Receives FDA Approval of Qutenza(TM) (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
Date:11/16/2009

is now poised to bring its lead product to patients and physicians. In addition, we continue to apply our knowledge and expertise in the development of other novel treatments for pain.

Our lead product, Qutenza(TM) (capsaicin) 8% patch, is a dermal delivery system containing a prescription strength of capsaicin that is currently approved in the United States and the European Union. Qutenza is expected to be launched by NeurogesX in the United States in the first half of 2010. In Europe, Qutenza will be marketed by Astellas Pharma Europe Ltd., (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc.

NeurogesX's second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies.

NeurogesX's early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: statements about the safety and efficacy of Qutenza(TM); the timing of launch and commercialization of Qutenza; and NeurogesX' plans to commercialize Qutenza with its own sales force. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limite
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NeurogesX Expands Commercial Operations Leadership Team
2. NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
3. NeurogesX to Present at JMP Securities Healthcare Focus Conference
4. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
5. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
6. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
7. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
8. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
9. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
10. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
11. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Pomerantz LLP is ... Inc. ("Vitae" or the "Company") (NASDAQ: VTAE ... S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ... and certain of its officers and/or directors have violated ... of 1934.  On February 27, 2015, ...
(Date:2/27/2015)... , Israele, February 27, 2015 ... nel suo sviluppo dell,innovativo sistema di monitoraggio dell,infarto ... primo trial sull,uomo-     ... nello sviluppo di nuovo sistema per il monitoraggio ... (CHF), ha annunciato oggi di aver concluso una ...
(Date:2/27/2015)... 2015 An aggressive campaign to reduce the ... of infection with a dangerous drug-resistant bacteria at The ... difficile, or C.diff, is a bacterium that can cause ... colon. A recent article in the New England Journal ... the United States " asserts that ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3
... approval of amendments, which may ... subpopulations, TOKYO, Japan and INDIANAPOLIS, Oct. 24 ,Daiichi ... Company,(NYSE: LLY ) today announced that enrollment of ... small prasugrel-related,pharmacodynamic clinical trials are being suspended until protocol,amendments ...
... health, we need to fast-track research and approvals,now, says ... the heels,of a study published this month in the ... oral cancer in the New England,Journal of Medicine, the ... the safety of human papillomavirus (HPV),vaccinations for males, and ...
Cached Medicine Technology:Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies 2Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies 3Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies 4The Oral Cancer Foundation Urges HPV Vaccination for Males 2The Oral Cancer Foundation Urges HPV Vaccination for Males 3
(Date:2/28/2015)... MD (PRWEB) February 28, 2015 The ... present its annual awards at the International Symposium on ... will be held at the Hyatt Regency Bethesda in ... for their dedicated work and commitment to the mission ... the Year Award will be presented to Miriam Ratner. ...
(Date:2/28/2015)... 28, 2015 Dr. Perry Patel ... area residents, recently announced a special offer for the ... treatment option for new and established patients at his Pismo ... a bright, white smile, Dr. Patel and his staff ... marked down from the regular price of $450. , ...
(Date:2/28/2015)... AZ (PRWEB) February 28, 2015 Kaylie ... and alcohol treatment center , and current student obtaining ... University, has implemented a weekly forum in psychoeducation on ... school in Flagstaff, AZ as part of her studies. ... big need for support and counseling at the high ...
(Date:2/28/2015)... ON (PRWEB) February 28, 2015 The ... to announce that they have officially relaunched their website. ... more user-friendly, but it contains a new section about ... access to read the full biographies of each Friedman ... portion of the website was designed to provide our ...
(Date:2/28/2015)... Javon Bea Mercy Health System CEO ... capable by the State of Illinois, enabling potential stroke ... Hospital. , The hospital was required to submit data ... stroke according to national standards of care for stroke ... bypass hospitals not designated as an Emergent Stroke Ready ...
Breaking Medicine News(10 mins):Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Friedman Dental Group Announces Their Updated Website 2Health News:Mercy Harvard Hospital Recognized as Leader in Stroke Care - Javon Bea 2
... shows that fetal cell transplantation for patients with ... of their medications altogether.// ,Parkinson’s disease ... Patients with Parkinson’s lack the chemical dopamine, which ... transplanting aborted human fetal tissue to replace the ...
... to the latest issue of Harvard Heart Letter, testing of ... Clinical testing of eye can predict the condition of the ... ,In a study headed by Dr. John I. Loewenstein, a ... relationship has been drawn between changing conditions of blood vessels ...
... use for cell phones that come complete with cameras: ... phone cameras to send pictures of wounds to specialists ... the wounds from the photos. ,The study involved ... seen in an outpatient clinic. Investigators had a physician ...
... new study shows that infants born under 5.5 pounds ... for developing // type 2 diabetes later in life. ... the only cause of prenatal malnourishment. Abnormal development of ... pressure, which damages vessels can also lead to malnourishment ...
... 100 patients at an ear , nose and throat clinic ... snoring // shouldn't expect to receive a diagnosis of obstructive ... examination alone instead an overnight sleep testing needs to be ... ,For the study, physicians evaluated the patients with a ...
... Dental Society's 140th Midwinter Meeting that begins in US ... over can take a peek to some very innovative ... display there. The convention is also one of the ... ,The showcase of products from 46 countries will ...
Cached Medicine News:
Unipolar temporary atrial pacing lead is smaller and thinner than Medtronics standard temporary pacing leads. It is well suited for thin, delicate, atrial tissue....
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: